Drug intelligence / Profile preview

Naxifylline

Development stage: Unknown
Lead developer: Gilead Sciences
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

Naxifylline is a chemical substance identified by its molecular formula C18H24N4O3 and molecular weight 344.41. It is classified as a purine derivative. While code names such as BG-9719, BG9719, and CVT-124 are associated with it, detailed information regarding its specific mechanism of action, primary indications, developers, or current development status is not publicly available in the provided sources.

Other names: 1H-PURINE-2,6-DIONE, 3,7-DIHYDRO-8-(3-OXATRICYCLO(3.2.1.0(SUP 2,4))OCT-6-YL)-1,3-DIPROPYL-, (1S-(1.ALPHA.,2.BETA.,4.BETA.,5.ALPHA.,6.ALPHA. ))-8-[(2S,5,6-exo)-5,6-epoxy-2-norbonyl]-1,3-dipropylxanthine

Targets

PDE (Phosphodiesterase family)ADRB2 (β2)ADORA2A (Adenosine A₂A Receptor)

Beyond the preview

Go deeper on Naxifylline.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Naxifylline.

Explore the full profile